# Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer

> **NCT02550327** · EARLY_PHASE1 · COMPLETED · sponsor: **Baylor Research Institute** · enrollment: 20 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Anakinra

## Key facts

- **NCT ID:** NCT02550327
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2021-06-14
- **Final completion:** 2021-06-14
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02550327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02550327, "Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02550327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*